Home › Companies › SUTRO BIOPHARMA INC. › 2023-2024

SUTRO BIOPHARMA INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and SUTRO BIOPHARMA INC.’s Form 8-K, filed 2024-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
143Asset managers
894Fund votes
2024-06-06Meeting date

Proxy season: 2023-2024 2024-2025

Explore SUTRO BIOPHARMA INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SUTRO BIOPHARMA INC.

These tallies are SUTRO BIOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SUTRO BIOPHARMA INC. — official shareholder meeting results, meeting held 2024-06-06
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Joseph M. Lobacki	49,578,870	--	--	1,393,863	13,906,799	Majority: yes
Elect Director: Daniel H. Petree	33,386,033	--	--	17,586,700	13,906,799	Majority: yes

Source: SUTRO BIOPHARMA INC., Form 8-K, filed with the SEC on 2024-06-10 — read the filing on EDGAR.

How asset managers voted at the SUTRO BIOPHARMA INC. 2023-2024 meeting

Each item below shows how the 143 asset managers that disclosed a SUTRO BIOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of SUTRO BIOPHARMA INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.8% fund support · no official result

FOR 97%

The 138 asset managers below cast 99.8% of the shares they voted on this item FOR (70,649,043 for, 110,736 against).

FOR: 70,649,043 (96.6%)AGAINST: 110,736 (0.2%)ABSTAIN: 2,346,085 (3.2%)

Largest asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at SUTRO BIOPHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
New York Life	26,000,000	0	For
SUVRETTA CAPITAL MANAGEMENT, LLC	7,608,682	0	For
Point72	5,847,686	0	For
BlackRock	4,939,416	0	For
MPM BioImpact LLC	4,121,208	0	For
Vanguard	3,030,875	0	For
Kynam Capital Management, LP	0	1,892,497	Abstain
BAILLIE GIFFORD & CO LTD	1,793,154	0	For
Fidelity	1,452,973	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,305,468	0	For
Samsara BioCapital, LLC	1,271,235	0	For
State Street	1,131,751	0	For
Two Sigma	1,071,064	0	For
Aquilo Capital Management, LLC	987,396	0	For
Dimensional	986,359	0	For
Goldman Sachs	640,292	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	587,776	0	For
PANAGORA ASSET MANAGEMENT INC	530,478	0	For
Ensign Peak Advisors, Inc	481,509	0	For
Candriam S.C.A.	0	440,369	Abstain
Nuveen	438,538	0	For
TIAA	434,955	0	For
ACADIAN ASSET MANAGEMENT LLC	427,262	0	For
Renaissance	370,407	0	For
DAFNA Capital Management LLC	334,079	0	For

Showing the 25 largest of 138 asset managers. See all 138 in the interactive database.

2. Election of Class III Directors: Daniel H. Petree

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD 35%

FOR: 33,386,033WITHHELD: 17,586,700

SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Daniel H. Petree”): 33,386,033 for, 17,586,700 withheld, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,794,334 outstanding shares: 41% for, 22% withheld (62% of the company cast a for/withheld vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (7,895,863 for, 0 against).

FOR 76%ABSTAIN 24%

FOR: 7,895,863 (76.4%)ABSTAIN: 2,435,226 (23.6%)

Largest asset managers voting on “Election of Class III Directors: Daniel H. Petree” at SUTRO BIOPHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,983,134	0	For
BlackRock	2,633,809	0	For
Fidelity	1,338,900	500	For
Dimensional	0	792,430	Abstain
Goldman Sachs	0	505,154	Abstain
TIAA	434,955	0	For
Equitable	108,716	75,300	For
Nationwide	941	164,047	Abstain
Charles Schwab	160,876	0	For
Columbia Threadneedle	0	149,005	Abstain
BRIDGEWAY FUNDS INC	0	145,200	Abstain
QUANTITATIVE MASTER SERIES LLC	113,702	0	For
American Century	0	74,398	Abstain
ETF Series Solutions	0	71,577	Abstain
Aberdeen	0	69,389	Abstain
Lincoln Financial	1,702	52,178	Abstain
GuideStone	0	48,744	Abstain
Russell Investments	30,928	0	For
AIG/SunAmerica	0	30,017	Abstain
John Hancock	0	27,512	Abstain
Northern Trust	0	27,332	Abstain
Brighthouse	0	25,793	Abstain
Bridge Builder Trust	24,111	0	For
Pacific Life	23,421	0	For
State Street	0	22,601	Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

3. Election of Class III Directors: Joseph M. Lobacki

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 49,578,870WITHHELD: 1,393,863

SUTRO BIOPHARMA INC.’s own tally for this item (“Elect Director: Joseph M. Lobacki”): 49,578,870 for, 1,393,863 withheld, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 81,794,334 outstanding shares: 61% for, 2% withheld (62% of the company cast a for/withheld vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,427,765 for, 0 against).

FOR 91%9%

FOR: 9,427,765 (91.3%)ABSTAIN: 903,324 (8.7%)

Largest asset managers voting on “Election of Class III Directors: Joseph M. Lobacki” at SUTRO BIOPHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,983,134	0	For
BlackRock	2,633,809	0	For
Fidelity	1,339,400	0	For
Dimensional	0	792,430	Abstain
Goldman Sachs	505,154	0	For
TIAA	434,955	0	For
Equitable	108,716	75,300	For
Nationwide	164,988	0	For
Charles Schwab	160,876	0	For
Columbia Threadneedle	149,005	0	For
BRIDGEWAY FUNDS INC	145,200	0	For
QUANTITATIVE MASTER SERIES LLC	113,702	0	For
American Century	74,398	0	For
ETF Series Solutions	71,577	0	For
Aberdeen	69,389	0	For
Lincoln Financial	51,802	2,078	For
GuideStone	48,744	0	For
Russell Investments	30,928	0	For
AIG/SunAmerica	30,017	0	For
John Hancock	25,747	1,765	For
Northern Trust	27,332	0	For
Brighthouse	12,574	13,219	Abstain
Bridge Builder Trust	24,111	0	For
Pacific Life	23,421	0	For
State Street	22,601	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

4. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.8%

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (10,317,705 for, 165 against).

FOR: 10,317,705 (99.9%)AGAINST: 165 (0.0%)ABSTAIN: 13,219 (0.1%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at SUTRO BIOPHARMA INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	2,983,134	0	For
BlackRock	2,633,809	0	For
Fidelity	1,339,400	0	For
Dimensional	792,430	0	For
Goldman Sachs	505,154	0	For
TIAA	434,955	0	For
Equitable	184,016	0	For
Nationwide	164,988	0	For
Charles Schwab	160,876	0	For
Columbia Threadneedle	149,005	0	For
BRIDGEWAY FUNDS INC	145,200	0	For
QUANTITATIVE MASTER SERIES LLC	113,702	0	For
American Century	74,398	0	For
ETF Series Solutions	71,577	0	For
Aberdeen	69,389	0	For
Lincoln Financial	53,880	0	For
GuideStone	48,744	0	For
Russell Investments	30,928	0	For
AIG/SunAmerica	30,017	0	For
John Hancock	27,512	0	For
Northern Trust	27,332	0	For
Brighthouse	12,574	13,219	Abstain
Bridge Builder Trust	24,111	0	For
Pacific Life	23,421	0	For
State Street	22,601	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

5. To approve the amendment of our 2018 Employee Stock Purchase Plan (the "ESPP") to (i) increase the overall limit on the number of shares that may be issued under our ESPP throughout its ten-year term, and (ii) make certain non-substantive clarifying revisions.

COMPENSATION

Combines 2 wordings of this item as funds reported it.

98% fund support · no official result

FOR 83%ABSTAIN 15%

The 50 asset managers below cast 98% of the shares they voted on this item FOR (10,096,996 for, 233,928 against).

FOR: 10,096,996 (82.6%)AGAINST: 233,928 (1.9%)ABSTAIN: 1,892,497 (15.5%)

Largest asset managers voting on “To approve the amendment of our 2018 Employee Stock Purchase Plan (the "ESPP") to (i) increase the overall lim” at SUTRO BIOPHARMA INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	2,983,134	0	0	For
BlackRock	2,633,809	0	0	For
Kynam Capital Management, LP	0	0	1,892,497	Abstain
Fidelity	1,339,400	0	0	For
Dimensional	792,430	0	0	For
Goldman Sachs	505,154	0	0	For
TIAA	434,955	0	0	For
Equitable	184,016	0	0	For
Nationwide	164,047	941	0	For
Charles Schwab	0	160,876	0	Against
Columbia Threadneedle	149,005	0	0	For
BRIDGEWAY FUNDS INC	145,200	0	0	For
QUANTITATIVE MASTER SERIES LLC	113,702	0	0	For
American Century	74,398	0	0	For
ETF Series Solutions	71,577	0	0	For
Aberdeen	69,389	0	0	For
Lincoln Financial	53,880	0	0	For
GuideStone	48,744	0	0	For
Russell Investments	0	30,928	0	Against
AIG/SunAmerica	30,017	0	0	For
John Hancock	27,512	0	0	For
Northern Trust	27,332	0	0	For
Brighthouse	12,574	13,219	0	Against
Bridge Builder Trust	24,111	0	0	For
Pacific Life	23,421	0	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 5 asset managers below cast 100% of the shares they voted on this item FOR (3,775,324 for, 0 against).

FOR: 3,775,324 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at SUTRO BIOPHARMA INC., 2023-2024
Asset manager	For	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,241,629	For
Eversept Partners, LP	1,488,828	For
ALGERT GLOBAL LLC	23,761	For
JPMorgan	19,734	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	1,372	For

Largest SUTRO BIOPHARMA INC. shareholders voting in 2023-2024

Ranked by the number of SUTRO BIOPHARMA INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 81,794,334 shares outstanding at the time of that meeting.

Top SUTRO BIOPHARMA INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	New York Life	31.79%
2	SUVRETTA CAPITAL MANAGEMENT, LLC	9.30%
3	Point72	7.15%
4	BlackRock	6.04%
5	MPM BioImpact LLC	5.04%
6	Vanguard	3.71%
7	Kynam Capital Management, LP	2.31%
8	BAILLIE GIFFORD & CO LTD	2.19%
9	Fidelity	1.78%
10	GEODE CAPITAL MANAGEMENT, LLC	1.60%

Reported SUTRO BIOPHARMA INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

SUTRO BIOPHARMA INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
S	7.06%	13G
Suvretta Capital Management, LLC	7.06%	DEF14A
Adage Capital Partners GP, LLC	5.46%	DEF14A
Vanguard Group	4.50%	13F
Integrated Core Strategies (US) LLC	4.22%	DEF14A
BVF Inc.	4.09%	DEF14A
Rubric Capital Management LP	4.09%	DEF14A
William J. Newell	2.11%	DEF14A
BlackRock	2.06%	13F
Dimensional Fund Advisors	1.60%	13F

Percentages above are of 81,794,334 shares outstanding, as reported by SUTRO BIOPHARMA INC. on its Form 10-Q dated 2024-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUTRO BIOPHARMA INC.’s 10-Q dated 2024-05-08. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At SUTRO BIOPHARMA INC.'s shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 143 asset managers reported how they voted in their SEC Form N-PX filings, covering 894 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. SUTRO BIOPHARMA INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — the reporting funds cast 99.8% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

SUTRO BIOPHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.